Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Abstract

A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor. Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.

Keywords

GefitinibEpidermal growth factor receptorLung cancerCancer researchTyrosine kinaseMedicineEpidermal growth factorTyrosine-kinase inhibitorMutationBiologyCancerInternal medicineReceptorGeneGenetics

Affiliated Institutions

Related Publications

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Sharon Barr , Stuart Thomson , Elizabeth Buck +10 more

Over 90% of all cancers are carcinomas, malignancies derived from cells of epithelial origin. As carcinomas progress, these tumors may lose epithelial morphology and acquire mes...

2008 Clinical & Experimental Metastasis 199 citations

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Elizabeth Buck , Alexandra Eyzaguirre , Sharon Barr +7 more

Abstract Overexpression and enhanced activation of the epidermal growth factor receptor (EGFR) is frequently observed in human carcinomas. Inhibitors of EGFR signaling have show...

2007 Molecular Cancer Therapeutics 186 citations

A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i>

Philipp Sievers , Martin Sill , Daniel Schrimpf +29 more

Abstract Background Malignant astrocytic gliomas in children show a remarkable biological and clinical diversity. Small in-frame insertions or missense mutations in the epiderma...

2020 Neuro-Oncology 112 citations

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer

Gerlinde Pilkington , Angela Boland , Tamara Brown +3 more

Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellen...

2015 Thorax 116 citations

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network

Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA ...

2014 Nature 5605 citations

Publication Info

Year: 2004
Type: article
Volume: 350
Issue: 21
Pages: 2129-2139
Citations: 11361
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

11361

OpenAlex

Cite This

APA Style

                            
                                
                                    Thomas J. Lynch, 
                                
                                    Daphne W. Bell, 
                                
                                    Raffaella Sordella
                                
                                et al.
                            
                            (2004). 
                            Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib. 
                            New England Journal of Medicine
                            , 350
                            (21)
                            , 2129-2139.
                            https://doi.org/10.1056/nejmoa040938
                        

Identifiers

DOI: 10.1056/nejmoa040938